Related Experiment Video
Updated: Sep 21, 2025
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
8.0K
Heart-Rate-Corrected QT Interval Response to Ramosetron during Robot-Assisted Laparoscopic Prostatectomy: A
Bora Lee1, So Yeon Kim1, Seung Hyun Kim1
1Department of Anesthesiology and Pain Medicine, Severance Hospital, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
Journal of Personalized Medicine
|May 28, 2022
Summary
Ramosetron is safe for preventing postoperative nausea and vomiting in robot-assisted laparoscopic prostatectomy (RALP) patients. The drug did not significantly affect heart-rate-corrected (QTc) intervals during RALP, even with the Trendelenburg position.
Area of Science:
- Anesthesiology
- Cardiology
- Surgical Oncology
Background:
- Ramosetron is used for postoperative nausea and vomiting (PONV).
- Robot-assisted laparoscopic prostatectomy (RALP) involves steep Trendelenburg positioning and CO2 pneumoperitoneum.
- Both RALP and ramosetron may prolong the heart-rate-corrected (QTc) interval.
Purpose of the Study:
- To evaluate the effect of ramosetron on QTc interval during RALP.
- To determine the safety of ramosetron in RALP patients regarding cardiac repolarization.
Main Methods:
- Fifty-six patients undergoing RALP were randomized into ramosetron (n=28) or control (n=28) groups.
- QTc intervals were measured at multiple time points: pre-induction, post-induction, during Trendelenburg positioning, post-supine, and end of surgery.
- Linear mixed models were used for statistical analysis.
Main Results:
- No significant difference in QTc intervals between the ramosetron and control groups over time (Pgroup×time = 0.111).
- A significant increase in QTc intervals was observed in both groups after adopting the Trendelenburg position compared to pre-induction (Ptime < 0.001).
- This QTc interval increase persisted throughout the surgical procedure in both groups.
Conclusions:
- Ramosetron can be safely administered for PONV prophylaxis in patients undergoing RALP.
- The cardiac safety of ramosetron is confirmed in the context of RALP, despite positional changes and pneumoperitoneum.
